资讯

Healio1 年
FDA expands indication for vosoritide to include children of all ages with achondroplasia
to include children of all ages with achondroplasia with open epiphyses, or open growth plates. As Healio previously reported, vosoritide was the first drug approved by the FDA to treat ...
The American Journal of Managed Care1 年
Vosoritide Approved for Achondroplasia in Children Under 5 Years by FDA
on October 20, 2023, the expanded indication in the United States now includes children of all ages with achondroplasia with open epiphyses–previously, vosoritide was indicated only for children ...
Medindia1 年
Medications and their Potential to Cause Increase 'Epiphyses premature fusion'
This page lists all known medications that could potentially lead to 'Epiphyses premature fusion' as a side effect. It's important to note that mild side effects are quite common with medications.